

28 SEPTEMBER 2023

## INVESTOR WEBINAR PRESENTATION

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company") is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 29th of September 2023 from 12:30pm AEST/ 10:30am AWST.

Marjan Mikel, CEO & Managing Director, will provide an overview of the Company which is an eHealth SaaS Company supporting respiratory healthcare management and remote patient monitoring.

This webinar can be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

[https://us02web.zoom.us/webinar/register/WN\\_od9F5ZAgSJGiF1F\\_kv83TA#/registration](https://us02web.zoom.us/webinar/register/WN_od9F5ZAgSJGiF1F_kv83TA#/registration)

A recorded copy of the webinar will be made available following the event.

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

---

### **About Respiri Limited – An RPM Business Augmented by R&D**

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is a pioneering presence in the Remote Patient Monitoring (RPM) and MedTech sectors. The company uses its innovative respiratory technology with a disruptive business model as an RPM provider to offer the only RPM program for respiratory disorders. As a differentiated RPM provider, Respiri's mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, respiratory disease. Respiri's globally unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled. Respiri is strategically positioned to revolutionise chronic disease management globally and is focused on the US market, where RPM services are reimbursed by Current Procedural Terminology (CPT) Code reimbursement. Learn more at [www.respiri.co/au](http://www.respiri.co/au)

### **About Access Telehealth**

Access Telehealth, a Respiri Limited subsidiary, is reshaping chronic care management in the US through best-in-class, patient-centric, reimbursed Remote Patient Monitoring (RPM) solutions. Our clinical team and software platform enable remote care delivery to patients with chronic diseases. The company provides a seamless and timely connection between patients and healthcare providers for better, cost-effective health outcomes. Discover more at [www.accessrpm.com](http://www.accessrpm.com)

### **About the wheezo® Medical Device**

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offerings, including wheezo®, visit [www.respiri.co/us](http://www.respiri.co/us)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

### **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.